​

Elevance Health (ELV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ELV Stock Forecast

Elevance Health stock forecast is as follows: an average price target of $542.14 (represents a 48.14% upside from ELV’s last price of $365.96) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

ELV Price Target

The average price target for Elevance Health (ELV) is $542.14 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $643.00 to $478.00. This represents a potential 48.14% upside from ELV's last price of $365.96.

ELV Analyst Ratings

Buy

According to 13 Wall Street analysts, Elevance Health's rating consensus is 'Buy'. The analyst rating breakdown for ELV stock is 0 'Strong Buy' (0.00%), 12 'Buy' (92.31%), 1 'Hold' (7.69%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Elevance Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024David WindleyJefferies$529.00$430.7722.80%44.55%
Oct 21, 2024Whit MayoLeerink Partners$515.00$430.7719.55%40.73%
Oct 18, 2024Sarah JamesRaymond James$485.00$432.5312.13%32.53%
Oct 18, 2024Ben HendrixRBC Capital$478.00$444.357.57%30.62%
Oct 18, 2024David MacDonaldTruist Financial$520.00$444.3517.02%42.09%
Oct 16, 2024Michael HaRobert W. Baird$625.00$483.8729.17%70.78%
Jul 18, 2024Ben HendrixRBC Capital$585.00$502.0616.52%59.85%
Jul 15, 2024David MacDonaldTruist Financial$620.00$535.5415.77%69.42%
Jun 24, 2024Erin WrightMorgan Stanley$643.00$534.4220.32%75.70%
May 29, 2024Michael HaRobert W. Baird$649.00$505.5228.38%77.34%
Apr 19, 2024Ben HendrixRBC Capital$575.00$525.199.48%57.12%
Apr 19, 2024AJ RiceUBS$605.00$525.1915.20%65.32%
Apr 19, 2024Stephen BaxterWells Fargo$600.00$525.1914.24%63.95%
Apr 19, 2024David WindleyJefferies$604.00$525.1915.01%65.05%
Apr 19, 2024Andrew MokBarclays$621.00$525.1918.24%69.69%
Nov 10, 2022Mizuho Securities$575.00$521.8810.18%57.12%
Jun 16, 2022Joseph FranceLoop Capital Markets$550.00$454.7620.94%50.29%
May 25, 2022Stephen BaxterWells Fargo$580.00$501.5315.65%58.49%
Apr 25, 2022BMO Capital$625.00$495.6126.11%70.78%
Apr 22, 2022Deutsche Bank$574.00$510.4012.46%56.85%
Apr 21, 2022Morgan Stanley$607.00$528.4514.87%65.87%
Apr 21, 2022Goldman Sachs$605.00$529.8414.19%65.32%
Apr 21, 2022Leerink Partners$555.00$529.844.75%51.66%
Apr 21, 2022Ben HendrixRBC Capital$544.00$522.874.04%48.65%
Apr 21, 2022Jonathan YongCredit Suisse$584.00$522.8711.69%59.58%
Apr 20, 2022Ann HynesMizuho Securities$510.00$529.84-3.74%39.36%
Apr 20, 2022David WindleyJefferies$625.00$529.8417.96%70.78%
Apr 20, 2022Michael NewshelEvercore ISI$335.00$529.84-36.77%-8.46%
Apr 11, 2022David MacDonaldTruist Financial$590.00$510.6415.54%61.22%
Apr 04, 2022Kevin CaliendoUBS$541.00$489.3410.56%47.83%
Jan 27, 2022Lisa GillJ.P. Morgan$500.00$434.6115.05%36.63%
Jan 27, 2022Ben HendrixRBC Capital$452.00$434.614.00%23.51%
Jan 27, 2022Matthew BorschBMO Capital$510.00$434.6117.35%39.36%
Jan 26, 2022Joseph FranceSeaport Global$480.00$427.2412.35%31.16%
Jan 26, 2022Michael NewshelEvercore ISI$335.00$427.24-21.59%-8.46%
Jan 11, 2022Lance WilkesBernstein$574.00$452.4626.86%56.85%
Jan 06, 2022Steve BaxterWells Fargo$523.00$438.2219.35%42.91%
Dec 14, 2021Nathan RichGoldman Sachs$517.00$432.7219.48%41.27%
Nov 30, 2021Justin LakeWolfe Research$433.00$403.967.19%18.32%
Oct 21, 2021Kevin FischbeckBank of America Securities$465.00$428.008.64%27.06%
Oct 21, 2021A.J. RiceCredit Suisse$486.00$428.0013.55%32.80%
Oct 21, 2021Steven ValiquetteBarclays$485.00$428.0013.32%32.53%
Oct 20, 2021Steven HalperCantor Fitzgerald$470.00$421.6811.46%28.43%

The latest Elevance Health stock forecast, released on Oct 21, 2024 by David Windley from Jefferies, set a price target of $529.00, which represents a 22.80% increase from the stock price at the time of the forecast ($430.77), and a 44.55% increase from ELV last price ($365.96).

Elevance Health Price Target by Period

1M3M12M
# Anlaysts-615
Avg Price Target-$525.33$576.93
Last Closing Price$365.96$365.96$365.96
Upside/Downside-100.00%43.55%57.65%

In the current month, the average price target of Elevance Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elevance Health's last price of $365.96. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Cowen & Co.BuyBuyHold
Oct 21, 2024JefferiesBuyBuyHold
Oct 21, 2024Leerink PartnersOutperformOutperformHold
Oct 18, 2024UBSBuyBuyHold
Oct 18, 2024Cantor FitzgeraldOverweightOverweightHold
Oct 18, 2024Wells FargoBuyBuyHold
Oct 18, 2024StephensUnderperformUnderperformHold
Oct 18, 2024RBC CapitalOutperformOutperformHold
Oct 10, 2024BarclaysOverweightOverweightHold
Aug 19, 2024Wells FargoBuyBuyHold
Aug 19, 2024StephensUnderperformUnderperformHold
Jul 19, 2024Cowen & Co.BuyBuyHold
Jul 18, 2024BarclaysOverweightOverweightHold
Jul 18, 2024Bank of America SecuritiesBuyNeutralDowngrade
Jul 18, 2024RBC CapitalOutperformOutperformHold
Jul 15, 2024Wells FargoBuyBuyHold
Jun 24, 2024Wells FargoBuyBuyHold
Jun 24, 2024UBSUnderperformUnderperformHold
Jun 11, 2024StephensOverweightOverweightHold
May 30, 2024Wells FargoBuyBuyHold
May 30, 2024UBSUnderperformUnderperformHold
Apr 19, 2024UBSBuyBuyHold
Apr 19, 2024Wells FargoOverweightOverweightHold
Apr 19, 2024JefferiesBuyBuyHold
Apr 19, 2024BarclaysOverweightOverweightHold
Apr 18, 2024Cantor FitzgeraldOutperformOutperformHold
Apr 04, 2024RBC CapitalOutperformOutperformHold
Apr 04, 2024Raymond JamesUnderperformUnderperformHold
Mar 06, 2024RBC CapitalOutperformOutperformHold
Feb 14, 2024Raymond JamesUnderperformUnderperformHold
Jan 25, 2024RBC CapitalOutperformOutperformHold
Jul 25, 2023Morgan StanleyOverweightOverweightHold
Apr 27, 2023Morgan StanleyOverweightUpgrade
Apr 24, 2023Wells FargoOverweightOverweightHold
Mar 28, 2023RBC CapitalOutperformUpgrade
Sep 09, 2022Bank of America SecuritiesBuyUpgrade
Aug 22, 2022SVB LeerinkOutperformUpgrade
Jun 16, 2022Loop Capital MarketsBuyInitialise
May 25, 2022Wells FargoOverweightOverweightHold
Apr 26, 2022Cowen & Co.OutperformOutperformHold
Apr 24, 2022Credit SuisseOutperformOutperformHold
Apr 04, 2022UBSBuyBuyHold

Elevance Health's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave ELV a "Buy" rating, the same as its previous rate.

Elevance Health Financial Forecast

Elevance Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$42.65B$42.85B$43.67B$42.17B$39.93B$39.94B$38.63B$38.09B$36.58B$35.82B$33.85B$32.38B$31.82B$31.16B$29.26B$29.62B$27.41B$26.67B
Avg Forecast$51.06B$51.44B$50.56B$49.14B$47.89B$47.97B$46.83B$45.55B$44.90B$43.47B$42.99B$42.49B$42.19B$42.76B$41.64B$40.92B$39.77B$39.29B$37.91B$37.39B$36.50B$35.35B$33.13B$32.97B$30.90B$29.86B$29.39B$28.69B$27.07B$25.89B
High Forecast$52.95B$53.35B$52.44B$50.96B$49.67B$49.75B$48.57B$47.10B$46.31B$43.47B$42.99B$42.49B$42.82B$44.35B$43.18B$42.44B$41.25B$39.29B$37.91B$37.39B$36.50B$35.35B$33.13B$32.97B$30.90B$29.86B$29.39B$28.69B$27.07B$25.89B
Low Forecast$48.56B$48.92B$48.08B$46.73B$45.54B$45.62B$44.54B$42.81B$43.29B$43.47B$42.99B$42.49B$41.13B$40.67B$39.60B$38.91B$37.82B$39.29B$37.91B$37.39B$36.50B$35.35B$33.13B$32.97B$30.90B$29.86B$29.39B$28.69B$27.07B$25.89B
# Analysts6612111098131496612999555566661010101099
Surprise %------------1.01%1.00%1.05%1.03%1.00%1.02%1.02%1.02%1.00%1.01%1.02%0.98%1.03%1.04%1.00%1.03%1.01%1.03%

Elevance Health's average Quarter revenue forecast for Mar 24 based on 6 analysts is $42.49B, with a low forecast of $42.49B, and a high forecast of $42.49B. ELV's average Quarter revenue forecast represents a -0.36% decrease compared to the company's last Quarter revenue of $42.65B (Dec 23).

Elevance Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6612111098131496612999555566661010101099
EBITDA------------$449.00M$32.73B$34.53B$3.33B$1.84B$2.81B$2.75B$2.90B$1.97B$2.56B$2.86B$2.65B$1.09B$895.00M$3.64B$2.55B$1.53B$1.98B
Avg Forecast$3.12B$3.14B$3.09B$3.00B$2.93B$2.93B$2.86B$2.78B$2.74B$2.66B$2.63B$3.31B$2.58B$2.61B$2.54B$3.01B$2.16B$2.09B$2.02B$2.73B$1.94B$1.88B$1.76B$2.44B$1.64B$1.59B$1.56B$2.55B$1.44B$1.38B
High Forecast$3.24B$3.26B$3.20B$3.11B$3.04B$3.04B$2.97B$2.88B$2.83B$2.66B$2.63B$3.97B$2.62B$2.71B$2.64B$3.61B$2.59B$2.09B$2.02B$3.28B$1.94B$1.88B$1.76B$2.93B$1.64B$1.59B$1.56B$3.06B$1.44B$1.38B
Low Forecast$2.97B$2.99B$2.94B$2.86B$2.78B$2.79B$2.72B$2.62B$2.65B$2.66B$2.63B$2.64B$2.51B$2.48B$2.42B$2.40B$1.73B$2.09B$2.02B$2.19B$1.94B$1.88B$1.76B$1.96B$1.64B$1.59B$1.56B$2.04B$1.44B$1.38B
Surprise %------------0.17%12.53%13.57%1.11%0.85%1.34%1.36%1.06%1.02%1.36%1.62%1.08%0.66%0.56%2.33%1.00%1.07%1.43%

6 analysts predict ELV's average Quarter EBITDA for Mar 24 to be $3.31B, with a high of $3.97B and a low of $2.64B. This is 636.21% upper than Elevance Health's previous annual EBITDA (Dec 23) of $449.00M.

Elevance Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6612111098131496612999555566661010101099
Net Income------------$856.00M$1.30B$1.86B$1.99B$949.00M$1.62B$1.65B$1.80B$1.13B$1.51B$1.79B$1.67B$551.00M$222.00M$2.28B$1.52B$934.00M$1.18B
Avg Forecast$1.37B$2.26B$2.77B$2.90B$1.28B$2.04B$2.35B$2.40B$927.53M$2.25B$2.33B$2.06B$1.30B$1.97B$2.05B$1.87B$1.24B$1.67B$1.81B$1.70B$1.19B$1.49B$1.48B$1.54B$590.93M$962.07M$2.04B$1.52B$906.26M$1.12B
High Forecast$1.44B$2.37B$2.90B$3.04B$1.34B$2.14B$2.46B$2.69B$1.54B$2.26B$2.33B$2.47B$1.32B$2.07B$2.15B$2.25B$1.49B$1.67B$1.81B$2.04B$1.19B$1.49B$1.48B$1.84B$590.93M$962.07M$2.04B$1.83B$906.26M$1.12B
Low Forecast$1.29B$2.12B$2.59B$2.72B$1.20B$1.91B$2.20B$1.90B$678.68M$2.25B$2.33B$1.65B$1.29B$1.85B$1.92B$1.50B$994.69M$1.67B$1.81B$1.36B$1.19B$1.49B$1.48B$1.23B$590.93M$962.07M$2.04B$1.22B$906.26M$1.12B
Surprise %------------0.66%0.66%0.91%1.06%0.76%0.97%0.91%1.06%0.94%1.01%1.21%1.08%0.93%0.23%1.12%1.00%1.03%1.05%

Elevance Health's average Quarter net income forecast for Mar 24 is $2.06B, with a range of $1.65B to $2.47B. ELV's average Quarter net income forecast represents a 140.77% increase compared to the company's last Quarter net income of $856.00M (Dec 23).

Elevance Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6612111098131496612999555566661010101099
SG&A---------------$4.80B$4.56B$4.51B$4.27B$4.34B$4.22B$3.95B$3.82B$3.92B$4.32B$5.30B$4.05B$3.78B$3.50B$3.42B
Avg Forecast$2.16B$2.18B$2.14B$2.08B$2.03B$2.03B$1.98B$1.93B$1.90B$1.84B$1.82B$4.96B$1.78B$1.81B$1.76B$4.51B$4.62B$5.59B$5.40B$4.10B$5.20B$5.03B$4.72B$3.62B$4.40B$4.25B$4.18B$3.78B$3.85B$3.69B
High Forecast$2.24B$2.26B$2.22B$2.16B$2.10B$2.10B$2.05B$1.99B$1.96B$1.84B$1.82B$5.95B$1.81B$1.88B$1.83B$5.41B$5.54B$5.59B$5.40B$4.92B$5.20B$5.03B$4.72B$4.35B$4.40B$4.25B$4.18B$4.54B$3.85B$3.69B
Low Forecast$2.05B$2.07B$2.03B$1.98B$1.93B$1.93B$1.88B$1.81B$1.83B$1.84B$1.82B$3.97B$1.74B$1.72B$1.67B$3.60B$3.69B$5.59B$5.40B$3.28B$5.20B$5.03B$4.72B$2.90B$4.40B$4.25B$4.18B$3.02B$3.85B$3.69B
Surprise %---------------1.07%0.99%0.81%0.79%1.06%0.81%0.78%0.81%1.08%0.98%1.25%0.97%1.00%0.91%0.93%

Elevance Health's average Quarter SG&A projection for Jun 23 is $1.76B, based on 9 Wall Street analysts, with a range of $1.67B to $1.83B. The forecast indicates a -63.31% fall compared to ELV last annual SG&A of $4.80B (Mar 23).

Elevance Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts6612111098131496612999555566661010101099
EPS------------$3.63$5.48$7.83$8.44$3.99$6.75$6.87$7.41$4.65$6.20$7.33$6.80$2.25$0.88$9.02$6.03$3.69$4.64
Avg Forecast$5.90$9.71$11.88$12.44$5.48$8.74$10.07$10.31$3.98$9.66$10.00$10.52$5.60$8.46$8.78$9.29$5.19$7.15$7.75$7.81$5.11$6.37$6.34$6.41$2.53$4.12$8.74$6.47$3.88$4.82
High Forecast$6.18$10.18$12.45$13.04$5.75$9.16$10.55$11.55$6.59$9.68$10.00$10.52$5.67$8.87$9.21$9.74$5.44$7.15$7.75$7.81$5.11$6.37$6.34$6.41$2.53$4.12$8.74$6.47$3.88$4.82
Low Forecast$5.52$9.09$11.12$11.65$5.13$8.19$9.43$8.16$2.91$9.63$10.00$10.52$5.53$7.92$8.22$8.70$4.86$7.15$7.75$7.81$5.11$6.37$6.34$6.41$2.53$4.12$8.74$6.47$3.88$4.82
Surprise %------------0.65%0.65%0.89%0.91%0.77%0.94%0.89%0.95%0.91%0.97%1.16%1.06%0.89%0.21%1.03%0.93%0.95%0.96%

According to 6 Wall Street analysts, Elevance Health's projected average Quarter EPS for Mar 24 is $10.52, with a low estimate of $10.52 and a high estimate of $10.52. This represents a 189.79% increase compared to ELV previous annual EPS of $3.63 (Dec 23).

Elevance Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CVSCVS Health$44.04$73.5066.89%Buy
CICigna$265.59$400.0050.61%Buy
ELVElevance Health$366.30$542.1448.00%Buy
CNCCentene$57.81$81.5040.98%Buy
UNHUnitedHealth Group$485.52$618.7527.44%Buy
HUMHumana$233.89$292.1324.90%Hold
MOHMolina Healthcare$291.78$347.0018.93%Hold
ALHCAlignment Healthcare$10.83$10.00-7.66%Buy

ELV Forecast FAQ

Is Elevance Health a good buy?

Yes, according to 13 Wall Street analysts, Elevance Health (ELV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 92.31% of ELV's total ratings.

What is ELV's price target?

Elevance Health (ELV) average price target is $542.14 with a range of $478 to $643, implying a 48.14% from its last price of $365.96. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Elevance Health stock go up soon?

According to Wall Street analysts' prediction for ELV stock, the company can go up by 48.14% (from the last price of $365.96 to the average price target of $542.14), up by 75.70% based on the highest stock price target, and up by 30.62% based on the lowest stock price target.

Can Elevance Health stock reach $500?

ELV's average twelve months analyst stock price target of $542.14 supports the claim that Elevance Health can reach $500 in the near future.

What are Elevance Health's analysts' financial forecasts?

Elevance Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $188.25B (high $195.09B, low $178.52B), average EBITDA is $11.5B (high $11.92B, low $10.91B), average net income is $8.07B (high $8.63B, low $7.2B), average SG&A $7.96B (high $8.25B, low $7.55B), and average EPS is $34.6 (high $37.02, low $30.9). ELV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $202.2B (high $209.7B, low $192.29B), average EBITDA is $12.36B (high $12.81B, low $11.75B), average net income is $9.31B (high $9.76B, low $8.71B), average SG&A $8.55B (high $8.87B, low $8.13B), and average EPS is $39.92 (high $41.85, low $37.38).

Did the ELV's actual financial results beat the analysts' financial forecasts?

Based on Elevance Health's last annual report (Dec 2023), the company's revenue was $171.34B, beating the average analysts forecast of $167.5B by 2.29%. Apple's EBITDA was $1.74B, missing the average prediction of $10.74B by -83.79%. The company's net income was $5.99B, missing the average estimation of $7.2B by -16.82%. Apple's SG&A was $0, missing the average forecast of $9.86B by -100.00%. Lastly, the company's EPS was $25.22, missing the average prediction of $32.13 by -21.51%. In terms of the last quarterly report (Dec 2023), Elevance Health's revenue was $42.65B, beating the average analysts' forecast of $42.19B by 1.09%. The company's EBITDA was $449M, missing the average prediction of $2.58B by -82.58%. Elevance Health's net income was $856M, missing the average estimation of $1.3B by -34.39%. The company's SG&A was $0, missing the average forecast of $1.78B by -100.00%. Lastly, the company's EPS was $3.63, missing the average prediction of $5.6 by -35.15%